Características de las pacientes con cáncer de ovario en el Hospital de San José, Bogotá D.C., 2009-2013
Profile of patients with ovarian cancer in the Hospital de San José, Bogota, 2009-2013
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Mostrar biografía de los autores
El cáncer de ovario presenta alta prevalencia con 238.719 casos reportados a nivel mundial, cuya mortalidad alcanza y supera el 50%, siendo la mayor causada por cáncer ginecológico. Objetivo: Describir las características de las pacientes diagnosticadas o tratadas por cáncer de ovario en el Servicio de Ginecología Oncológica del Hospital de San José en el periodo 2009-2013.
Materiales y métodos: Serie de casos retrospectiva.
Resultados: Se incluyeron 68 pacientes con edad promedio de 49 años (DE: 15,5, mínima: 14 y máxima: 82); 57,5% (n = 39) fueron posmenopáusicas. El tipo histológico seroso papilar fue el más común en pre y menopáusicas. El 70,6% se diagnosticaron en estadios iii-iv. Se logró citorreducción óptima (R1) o total (R0) en el 40,9%. Se administró quimioterapia adyuvante al 74,24%. La supervivencia libre de recurrencia fue de 63,23% y la supervivencia global de 54,41%.
Conclusión: En nuestra población el cáncer de ovario se diagnosticó en edades más tempranas que lo reportado a nivel mundial. Coincidiendo con la literatura la histología más frecuente fue el seroso papilar, que se detectó en etapas avanzadas y con alta mortalidad.
Visitas del artículo 299 | Visitas PDF 209
Descargas
1. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Internet] Ginebra: World Health Organization [citado 10 Feb 2015]. Disponible en: http://globocan., iarc., fr/Default, aspx.
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.
3. Prat J. Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.
4. MW G. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420–32.
5. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al. SGO white paper on ovarian cancer: Etiology, screening and surveillance. Gynecol Oncol. 2010;119:7–17.
6. Shih KR. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–8.
7. Kaye S, Brown R, Gabra H, Gore ME, editores. Emerging therapeutic targets in ovarian cancer. New York: Springer Science; 2011. p. 278.
8. Di Saia PJ, Creasman WT. Clinical gynecologic oncology. Philadelphia, PA: Elsevier; 2007.
9. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S161–92.
10. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IAPS Press; 2003. p. 432.
11. Berek JS, Hacker NF. Berek & Hacker’s gynecologic oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2010.
12. Giede KK, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol. 2005;99:447–61.
13. Jacobs OD, Faibanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating ultrasound and menopausal status for the preoperative diagnosis of ovarian cancer. BJOG. 1990;97:922–9.
14. American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice. Committee opinion n. o 477: The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;117(3):742-6.
15. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol. 2007;110:841–8.
16. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117:1289–97.
17. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.
18. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.
19. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: Prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104:863–70.
20. Karlsen MA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4. CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127:379–83.
21. Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.
22. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.
23. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332:629–34.
24. National Comprehensive Cancer Network. NCCN Guidelines. [Internet] Fort Washington: National Comprehensive Cancer Network [citado 15 Oct 2015]. Disponible en: http://www. nccn.org/professionals/physician gls/f guidelines.asp
25. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 2001;84:714–21.
26. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: A systematic review and meta-analysis. Cancer Prev Res (Phila). 2012;5:901–10.
27. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.
Información
Palabras clave
